Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intermediate Value Theorem01:25

The Intermediate Value Theorem

354
The Intermediate Value Theorem is a foundational result in calculus that guarantees the existence of solutions within certain intervals for continuous functions. Formally, the Intermediate Value Theorem states that if a function f is continuous on the closed interval [a, b], and if N is any value between f(a) and f(b), then there exists at least one c ∈ (a, b) such that f(c) = N. This theorem is instrumental in proving the existence of roots and in analyzing the behavior of continuous...
354
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

468
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
468
Actuarial Approach01:20

Actuarial Approach

341
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
341
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

664
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
664
Friedman Two-way Analysis of Variance by Ranks01:21

Friedman Two-way Analysis of Variance by Ranks

522
Friedman's Two-Way Analysis of Variance by Ranks is a nonparametric test designed to identify differences across multiple test attempts when traditional assumptions of normality and equal variances do not apply. Unlike conventional ANOVA, which requires normally distributed data with equal variances, Friedman's test is ideal for ordinal or non-normally distributed data, making it particularly useful for analyzing dependent samples, such as matched subjects over time or repeated measures...
522
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

894
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
894

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.

The oncologist·2026
Same author

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.

JAMA network open·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

692

Interim futility analysis with intermediate endpoints.

Bryan Goldman1, Michael LeBlanc, John Crowley

  • 1Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, San Antonio, TX 78245-3217, USA. bgoldman@fhcrc.org

Clinical Trials (London, England)
|February 20, 2008
PubMed
Summary
This summary is machine-generated.

Using an intermediate endpoint for interim futility testing in Phase III trials can significantly increase the chance of stopping early for futility. This approach may reduce trial duration and patient resource use without compromising efficacy power.

More Related Videos

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

1.2K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K

Related Experiment Videos

Last Updated: Mar 2, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

692
The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

1.2K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Oncology Research

Background:

  • Phase III trials often include interim analyses for efficacy and futility testing.
  • Futility testing traditionally uses primary outcomes at low significance levels.
  • Slowly accruing overall survival data can delay futility assessment.

Purpose of the Study:

  • To investigate the incorporation of intermediate endpoints into interim futility testing for Phase III trials.
  • To evaluate the impact of using intermediate endpoints on early trial termination for futility.

Main Methods:

  • Simulation studies using a two-stage exponential survival model.
  • Analysis of simulated survival data under null and alternative hypotheses.
  • Comparison of futility testing using overall survival, progression-free survival (PFS), and composite endpoints.

Main Results:

  • Incorporating PFS substantially increased the probability of early futility stopping under the null hypothesis.
  • Using a composite endpoint reduced average patient accrual by 6-11% across settings.
  • Savings in study duration were significant, especially in long-survival scenarios.
  • Negligible loss of statistical power was observed under the alternative hypothesis.

Conclusions:

  • Suitable intermediate endpoints can enhance interim futility monitoring in Phase III trials.
  • This strategy may lead to considerable reductions in trial duration and patient resources.
  • No substantial compromise in the primary efficacy test's power was detected.
  • Further research is needed on modified stopping rules for greater savings.